JACS Au,
Journal Year:
2024,
Volume and Issue:
4(12), P. 4655 - 4672
Published: Dec. 11, 2024
Electrochemical
biosensors
are
gaining
attention
as
powerful
tools
in
cancer
diagnosis,
particularly
liquid
biopsy,
due
to
their
high
efficiency,
rapid
response,
exceptional
sensitivity,
and
specificity.
However,
the
complexity
of
intra-
intertumor
heterogeneity,
with
variations
genetic
protein
expression
profiles
epigenetic
modifications,
makes
electrochemical
susceptible
false-positive
or
false-negative
diagnostic
outcomes.
To
address
this
challenge,
there
is
growing
interest
simultaneously
analyzing
multiple
biomarkers
reveal
molecular
characteristics
tumor
heterogeneity
for
precise
diagnosis.
In
Perspective,
we
highlight
recent
advancements
utilizing
a
specific
emphasis
on
multitarget
analysis
including
tumor-associated
nucleic
acids,
markers,
extracellular
vesicles,
cells.
These
hold
significant
promise
improving
precision
early
diagnosis
monitoring,
well
potentially
offering
new
insights
into
personalized
management.
ACS Sensors,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
With
the
goal
of
impacting
patient
quality
life
and
outcomes,
sensor
science
offers
significant
potential
to
revolutionize
healthcare
by
providing
advances
in
detection
molecular
biomarkers
for
personalized
clinical
technologies.
The
community
has
achieved
technical
advancements
that
can
impact
diagnostics,
health
monitoring,
disease
treatment;
however,
many
innovations
remain
confined
laboratory,
failing
bridge
translational
gap
between
research
real-world
applications.
This
perspective
presents
a
new
direction
community,
where
development
centers
on
needs
experiences
primary
beneficiaries:
patients.
We
provide
guidelines
resources
researchers
engage
with
patients
early
continuously
throughout
process
inform
specifications
better
align
technologies
needs,
improving
their
adoption
impact.
also
present
examples
implementing
patient-centered
approach
planning
engagement
research.
In
design
impactful
sensors
patients,
must
expand
focus
beyond
embrace
approach,
which
will
likely
lead
opportunities
collaboration
evolution
community.
Biosensors,
Journal Year:
2025,
Volume and Issue:
15(4), P. 203 - 203
Published: March 21, 2025
Ovarian
cancer
(OC)
is
one
of
the
leading
causes
gynecological
cancer-related
death
worldwide.
Late
diagnosis
at
advanced
stages
OC
reason
for
a
higher
mortality
rate.
Earlier
and
proper
treatment
are
important
improving
prognosis
patients.
Biosensors
offer
accurate,
low-cost,
rapid,
user-friendly
devices
that
can
be
employed
detection
OC-specific
biomarkers
in
early
stage.
Therefore,
it
to
consider
potential
biological
fluids
confirm
prognosis.
Out
many
biomarkers,
most
commonly
tested
clinically
antigen
125
(CA-125).
However,
CA-125
considered
poor
biomarker
diagnosis.
Several
biosensing
methods
were
developed
sensitive
quantitative
each
biomarker.
In
abnormal
expression
patients,
nucleic
acids,
enzymes,
cells,
exosomes
used
as
target
construction
biosensors.
This
review
focuses
on
development
various
using
multiple
methods.
Here,
we
describe
origin
significance
OC-associated
working
principle
biosensors,
classification
biosensors
based
their
recognition
elements
signal
transducers.
The
modes
sensitivity
sensors
discussed.
Finally,
challenges
fabrication,
obstacles
clinical
application,
future
prospects
